EVIDENCE HEATMAP / RESEARCH RECORD
TB-500 research, graded by how hot the data run
Actin sequestration is structurally established. Wound, neuro, and hair findings are animal-confirmed for the parent protein. The human record for the fragment is empty — and the angiogenesis that aids repair is also the safety signal.
TB-500 Mechanism of Action: Actin Sequestration and PINCH-ILK-Akt Signaling
The TB-500 mechanism of action begins at a single target: monomeric, globular (G-) actin. The LKKTETQ motif carried by TB-500 is the actin-binding core of thymosin beta-4, and X-ray crystallography of a gelsolin-domain-1–Tβ4 hybrid bound to actin resolved the interaction at 2 Å, establishing that the protein forms a 1:1 complex and sequesters the monomer by capping both ends to prevent polymerization [1]. This actin-buffering is the foundational, structurally confirmed fact of the whole family — the hottest cell in the matrix.
From that buffered actin pool, the downstream effects follow. Thymosin beta-4 promotes the migration of keratinocytes, endothelial cells, myoblasts, and progenitor cells, drives angiogenesis, reduces myofibroblast number and scarring, and limits apoptosis and inflammation after injury [5]. In the heart specifically, the protein formed a functional complex with PINCH and integrin-linked kinase, activating Akt and enhancing cardiomyocyte survival [2].
The honest caveat sits on every downstream claim: these pathways are characterized largely for full-length Tβ4 (~4963 Da). It is not established in controlled human trials that the isolated 889 Da fragment reproduces them at the doses used in peptide research [11].
TB-500 Benefits Reported in Preclinical Research
The TB-500 benefits reported in the literature are tissue-repair benefits, and they are real findings in animal and in-vitro models — with the consistent qualifier that they are unproven in humans for the fragment.
Wound healing is the most quantified. In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, raised wound contraction by at least 11% by day 7, and increased collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration 2-to-3-fold [3]. Connective tissue has one direct finding — thymosin beta-4 enhanced medial collateral ligament healing in rats [5]. Hair-follicle bulge stem cells were activated by nanomolar Tβ4, accelerating hair growth in rats and mice [5].
A 2026 narrative review placed TB-500 and BPC-157 among unapproved peptides that show favorable tissue-repair outcomes in animal models while rigorous human safety data remain scarce [11]. The benefits are a preclinical record, not a human one.
The tumor and angiogenesis safety signal
The same property that makes thymosin beta-4 a repair molecule is the basis of its main theoretical risk. Tβ4 promotes endothelial migration and new vessel formation — and the tumor and angiogenesis safety signal follows directly: the protein is overexpressed in several cancers, including pancreatic and colorectal, and is implicated in metastasis and tumor angiogenesis [11]. The pro-migratory, pro-angiogenic activity that aids healing could, in principle, support tumor progression. This is an unresolved signal, not a quantified human risk.
The rest of the safety picture is defined by absence. There are no long-term human safety studies of the TB-500 fragment. The only human dosing data — the Phase 1 intravenous study of full-length Tβ4 — reported only infrequent mild-to-moderate adverse events up to 1260 mg, with no dose-limiting toxicities and no serious adverse events [6]. That is reassuring for the parent protein at those doses; it is not a safety profile for the fragment.
What are the side effects of TB-500?
Human safety data for the fragment are scarce. The Phase 1 intravenous study of full-length thymosin beta-4 reported only mild-to-moderate adverse events up to 1260 mg with no dose-limiting toxicities [6]. The main theoretical concern is the unresolved tumor-angiogenesis signal, since Tβ4 is overexpressed in several cancers [11].
Is TB-500 safe for long-term use?
There are no long-term human safety studies of the TB-500 fragment. The tumor-angiogenesis signal [11] and the absence of completed controlled trials mean long-term safety is unknown. The only human data come from a short Phase 1 intravenous study of the full-length parent protein, not the fragment [6].
What is the difference between TB-500 and BPC-157?
TB-500 and BPC-157 are distinct molecules with distinct origins. TB-500 is the actin-binding heptapeptide fragment (Ac-LKKTETQ) of thymosin beta-4; BPC-157 is a separate, gastric-derived pentadecapeptide. They are grouped together in popular discussion because both are studied for tissue repair and both are unapproved.
The shared status is the honest common ground. A 2026 Sports Medicine review listed both TB-500/thymosin beta-4 and BPC-157 among unapproved peptides that show favorable animal-model tissue-repair outcomes but lack rigorous human safety data and operate largely outside regulatory oversight [11]. The mechanisms differ; the evidence maturity is similar — preclinical, not clinical.
Mixed and negative results cool the narrative
An honest heatmap shows the cold cells too. In dystrophin-deficient (mdx) mice, chronic thymosin beta-4 increased the number of regenerating muscle fibers but did not improve muscle strength, cardiac function, or fibrosis [5] — a recruitment effect without a functional payoff. The neuro data are non-monotonic rather than dose-linear: in a rat embolic-stroke study, 2 and 12 mg/kg improved neurological function while 18 mg/kg did not [4], undermining the "more is better" rationale behind community loading protocols.
Recent fibrosis work adds nuance rather than a clean direction. Thymosin beta-4 ameliorated liver fibrosis through the MAPK/NF-κB pathway in one rodent model [14], yet hepatic-stellate-cell-specific deletion of Tβ4 also reduced liver fibrosis in another [15] — context-dependent, not uniformly anti-fibrotic.
Does TB-500 work for muscle tears and recovery from exercise?
Thymosin beta-4 recruits myoblasts to injured muscle in animal models, but in dystrophin-deficient mice it increased regenerating fibers without improving strength [5]. Human exercise-recovery efficacy for the TB-500 fragment is unproven. The recruitment effect has not translated to a measured functional gain in these models.
Does TB-500 cause cancer or promote tumor growth?
Thymosin beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis [11]. The pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression. This is an unresolved safety signal, not a demonstrated human cancer risk for the fragment.
Are there any human clinical trials on TB-500?
No completed controlled trials of the TB-500 fragment exist. Human data are limited to full-length thymosin beta-4: a Phase 1 intravenous safety study, well tolerated to 1260 mg [6], and topical ophthalmic dry-eye RCTs of the clinical-grade formulation. Efficacy of the 7-mer in humans is not established.
How does TB-500 work?
Its LKKTETQ motif binds and sequesters monomeric G-actin, regulating cytoskeletal dynamics and cell migration [1]. Full-length thymosin beta-4 additionally drives angiogenesis and PINCH-ILK-Akt survival signaling in animal models [2]. The fragment carries the actin-binding core but is not proven to reproduce the full protein's downstream effects.
Can TB-500 help with tendon injuries and ligament repair?
Thymosin beta-4 enhanced medial collateral ligament healing in rats, one of few direct connective-tissue findings [5]. Human tendon and ligament efficacy of the fragment is unproven. Most of the repair literature concerns wound and epithelial tissue rather than tendon specifically.
Does TB-500 promote angiogenesis and is that a safety concern?
Yes to both. Thymosin beta-4 promotes endothelial migration and new vessel formation, which aids tissue repair [5]. The same activity is the basis of the tumor-angiogenesis concern, since the protein is implicated in tumor vascularization and is overexpressed in several cancers [11].
Does TB-500 have neuroprotective effects on the brain?
In a rat embolic-stroke dose-response study, intraperitoneal thymosin beta-4 at 2 and 12 mg/kg improved neurological function while 18 mg/kg did not — a non-monotonic response [4]. The benefit is animal-only; there is no human neuroprotection evidence for the TB-500 fragment.
Does TB-500 increase hair growth?
Nanomolar thymosin beta-4 activated hair-follicle bulge stem cells and accelerated hair growth in rats and mice [5]. No human hair-growth evidence exists for the TB-500 fragment. The finding sits in the preclinical band and has not been tested in controlled human trials.
Does TB-500 reduce inflammation?
Full-length thymosin beta-4 has reported anti-inflammatory and anti-apoptotic signaling after injury [5], and recent rodent work shows anti-fibrotic effects in liver via the MAPK/NF-κB pathway [14]. Clinical anti-inflammatory benefit for the fragment is unestablished, and the fibrosis role is context-dependent rather than uniform [15].
Does TB-500 help wound healing?
Full-length thymosin beta-4 accelerated re-epithelialization by 42% at 4 days and up to 61% at 7 days in a rat wound model, with increased contraction, collagen, and angiogenesis [3]. The fragment carries the actin-binding domain that underlies this activity, but human wound efficacy is unproven.